Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9733111 | 0.86 | SORD (0.38) | HTTALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL7811500 | 0.86 | — | — | |
| SCHEMBL27344928 | 0.82 | CYP1A2 (0.47) | HTTALDH1A1SMN1; SMN2CNR2KDM4E | |
| SCHEMBL2438010 | 0.80 | CYP1A2 (0.50) | HTTALDH1A1SMN1; SMN2CNR2NPC1 | |
| SCHEMBL5754979 | 0.79 | ALDH1A1 (0.61) | HTTALDH1A1SMN1; SMN2CNR2MEN1 | |
| SCHEMBL229138 | 0.77 | MEN1 (0.50) | HTTALDH1A1SMN1; SMN2CNR2MEN1 | |
| SCHEMBL2439624 | 0.77 | BPTF (0.53) | HTTALDH1A1KDM4EHSD17B10 | |
| Water SCHEMBL27506673 | 0.76 | BPTF (0.51) | HTTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL106639 | 0.69 | MEN1 (0.54) | HTTALDH1A1SMN1; SMN2CNR2MEN1 | |
| SCHEMBL21423998 | 0.69 | BPTF (0.62) | HTTALDH1A1SMN1; SMN2CNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119410585-A | Gastrointestinal stromal tumor organoid culture solution and use method and application thereof | 福建瑞庚生物科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-2874632-B1 | TRIAZINE COMPOUND HAVING PI3K-ALPHA AND MTOR INHIBITING ACTIVITY | SPHAERA PHARMA PTE LTD (SG) | 2020-06-17 | — | — | EP | disclosed |
| EP-2364302-B1 | TRIAZINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIV BASEL (CH) | 2016-10-05 | — | — | EP | disclosed |
| CN-102209714-B | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIV BASEL | 2015-03-25 | — | — | CN | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| CN-102209714-A | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIV BASEL | 2011-10-05 | — | — | CN | disclosed |
| EP-2364302-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2011-09-14 | — | — | EP | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| CN-1835946-B | Epoxy compound and cured epoxy resin product | SUMITOMO CHEMICAL CO | 2010-06-16 | — | — | CN | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009120094-A3 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| CN-1835946-A | Epoxy compound and cured epoxy resin product | SUMITOMO CHEMICAL CO (JP) | 2006-09-20 | — | — | CN | disclosed |
| US-5585423-A | POLYGLUTARIMIDE SHEETS, FILMS OR MOLDINGS CONTAINING HINDERED AMINE AND BENZOTRIAZOLE PHOTOSTABILIZERS | ROHM AND HAAS COMPANY (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0404311-A1 | Ultraviolet resistant glutarimide polymers | ROHM AND HAAS COMPANY (US) | 1990-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | HTT 4359/4885ALDH1A1 2617/4885SMN1; SMN2 3197/4885 |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | HTT 3381/4885ALDH1A1 3410/4885SMN1; SMN2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.